CodexisCDXS
CDXS logo
Fair Value
US$7.08
Share price01 May
US$1.5678.0% undervalued intrinsic discount
Loading
1Y-48.17%
7D6.12%

ECO Platform Partnerships Will Transform Pharma Manufacturing

Analyst Consensus Target compiles analysts opinions to create narratives on stocks using the Analysts Consensus Price Target, forecasted revenue and earnings figures, as well as the transcripts of earnings calls.

Published
29 Mar 25
Updated
01 May 25
Views
70
Not Invested

Shared on 01 May 25

Fair value Increased 53%
Read more
1 viewusers have viewed this narrative update

Shared on 24 Apr 25

Fair value Decreased 24%
Read more
3 viewsusers have viewed this narrative update

Shared on 17 Apr 25

Read more
0 viewsusers have viewed this narrative update

Shared on 09 Apr 25

Read more
1 viewusers have viewed this narrative update

Shared on 02 Apr 25

Fair value Decreased 13%
Read more
1 viewusers have viewed this narrative update

Fair Value vs Share Price

US$7.08
vs US$1.5678.0% undervalued intrinsic discount
PastFuture-82m138m2014201720202023202520262028Revenue US$138.3mEarnings US$19.6m
34.3%
Revenue growth
14.2%
Profit margin

Recent News & Updates

No updates

Recent updates

No updates

Stay ahead on Codexis

  • Fair value estimate changes
  • Narrative and analyst updates
  • Key company announcements

Company analysis

High growth potential with excellent balance sheet.

Market capUS$175.2m
PB5.2x
Estimated Growth21.6%
Dividend YieldN/A
Full analysis

CEO & management

Alison Moore
CEO
1.8yrs
CEO Tenure

Provides technology solutions for therapeutics manufacturing, leveraging its proprietary CodeEvolver technology platform to discover, develop, enhance, and commercialize novel enzymes in the United States, Canada, Latin America, Europe, the Middle East, Africa, Australia, New Zealand, Southeast Asia, and China.